Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01552434
Other study ID # 2012-0061
Secondary ID NCI-2012-0034720
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date March 16, 2012
Est. completion date March 31, 2026

Study information

Verified date April 2024
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I trial studies the side effects and best dose of bevacizumab and temsirolimus alone or in combination with valproic acid or cetuximab in treating patients with a malignancy that has spread to other places in the body or other disease that is not cancerous. Immunotherapy with bevacizumab and cetuximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether bevacizumab and temsirolimus work better when given alone or with valproic acid or cetuximab in treating patients with a malignancy or other disease that is not cancerous.


Description:

PRIMARY OBJECTIVES: I. To determine the maximum tolerated doses (MTDs) and dose-limiting toxicities (DLTs) of treatment with bevacizumab and temsirolimus in combination and plus valproic acid or cetuximab. SECONDARY OBJECTIVES: I. Preliminary descriptive assessment of anti-tumor efficacy of each combination. II. Preliminary assessment of the pharmacokinetic, pharmacodynamic markers of target inhibition and correlates of response (optional). OUTLINE: This is a dose-escalation study of bevacizumab and temsirolimus. Patients are assigned to 1 of 3 treatment groups. GROUP I: Patients receive temsirolimus intravenously (IV) over 30-60 minutes on days 1, 8, 15, and 22; bevacizumab IV over 30-90 minutes on days 1 and 15; and cetuximab IV over 1-2 hours on days 1, 8, 15, and 22. GROUP II: Patients receive temsirolimus and bevacizumab as in Group I and valproic acid orally (PO) daily on days 1-7 and 15-21. GROUP III: Patients receive temsirolimus and bevacizumab as in Group I. In all groups, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 155
Est. completion date March 31, 2026
Est. primary completion date March 31, 2026
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patients with advanced or metastatic cancer that is refractory to standard therapy, relapsed after standard therapy, or have no standard therapy that induces a complete response of at least 10% or improves survival by at least three months; in addition, patients with disease that are "benign" by pathology, but relentlessly progressive, leading to disability, pain, and premature death in the majority of cases (including, but not limited to lymphangioleiomyomatosis [LAM], type 2 neurofibromatosis [NF], Erdheim Chester disease, and Castleman's disease) may also be considered for enrollment - Patients should be at least four weeks from the last day of therapeutic radiation or cytotoxic chemotherapy or from antibody therapy, or at least five half-lives from non-cytotoxic targeted or biologic therapy; patients may have received palliative radiation immediately before (or during) treatment provided radiation is not to the only target lesion available - Eastern Cooperative Oncology Group (ECOG) performance status =< 2 - Karnofsky >= 60% - Lansky performance status of >= 60% for participants 16 years old or younger - Absolute neutrophil count >= 1,000/mL - Platelets >= 50,000/mL - Creatinine =< 3 X upper limit of normal (ULN) - Total bilirubin =< 3.0 - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 5 X ULN - Fasting level of total cholesterol of no more than 350 mg/dL - Triglyceride level of no more than 400 mg/dL - Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days after the last dose - Ability to understand and the willingness to sign a written informed consent document - Patients may not be receiving any other investigational agents and/or any other concurrent anticancer agents or therapies Exclusion Criteria: - Patients with clinically significant unexplained bleeding within 28 days prior to entering the study - Uncontrolled systemic vascular hypertension (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg on medication) - Patients with clinically significant cardiovascular disease: History of CVA (cerebrovascular accident) within 6 months, myocardial infarction or unstable angina within 6 months, unstable angina pectoris - Pregnant or breast-feeding women - History of hypersensitivity to bevacizumab, murine products, or any component of the formulation - History of hypersensitivity to temsirolimus or its metabolites (including sirolimus), polysorbate 80, or to any component of the formulation - History of hypersensitivity to cetuximab, murine products, or any component of the formulation - Patients that are taking cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) inducers and/or inhibitors; if a patient has a history of taking CYP3A4 inducers and/or inhibitors prior to enrollment on the protocol, it is strongly recommended that the patient stops the drug and waits at least 5 half-lives of said drug before initiating therapy on protocol - Colorectal cancer patients with known v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation (for the arm combining bevacizumab, temsirolimus and cetuximab) - Patients who have had major surgery within 6 weeks of enrollment in the study

Study Design


Related Conditions & MeSH terms

  • Advanced Malignant Neoplasm
  • Breast Neoplasms
  • Carcinoma
  • Castleman Disease
  • Digestive System Carcinoma
  • Erdheim-Chester Disease
  • Genital Neoplasms, Female
  • Genital Neoplasms, Male
  • Lip and Oral Cavity Carcinoma
  • Lymphangioleiomyomatosis
  • Malignant Endocrine Neoplasm
  • Malignant Female Reproductive System Neoplasm
  • Malignant Male Reproductive System Neoplasm
  • Malignant Neoplasm
  • Malignant Respiratory Tract Neoplasm
  • Malignant Thoracic Neoplasm
  • Malignant Urinary System Neoplasm
  • Mesothelial Neoplasm
  • Metastatic Malignant Neoplasm
  • Metastatic Urothelial Carcinoma
  • Neoplasms
  • Neurofibromatoses
  • Neurofibromatosis 2
  • Neurofibromatosis Type 2
  • Pharyngeal Neoplasms
  • Recurrence
  • Recurrent Adult Soft Tissue Sarcoma
  • Recurrent Breast Carcinoma
  • Recurrent Childhood Soft Tissue Sarcoma
  • Recurrent Digestive System Carcinoma
  • Recurrent Female Reproductive System Carcinoma
  • Recurrent Male Reproductive System Carcinoma
  • Recurrent Malignant Neoplasm
  • Recurrent Pharyngeal Carcinoma
  • Recurrent Thyroid Gland Carcinoma
  • Refractory Malignant Neoplasm
  • Respiratory Tract Neoplasms
  • Sarcoma
  • Soft Tissue Neoplasm
  • Soft Tissue Neoplasms
  • Stage III Breast Cancer AJCC v7
  • Stage III Pharyngeal Cancer
  • Stage IIIA Breast Cancer AJCC v7
  • Stage IIIB Breast Cancer AJCC v7
  • Stage IIIC Breast Cancer AJCC v7
  • Stage IV Breast Cancer AJCC v6 and v7
  • Stage IV Pharyngeal Cancer
  • Stage IVA Pharyngeal Cancer
  • Stage IVB Pharyngeal Cancer
  • Stage IVC Pharyngeal Cancer
  • Thoracic Neoplasms
  • Thyroid Diseases
  • Thyroid Gland Neoplasm
  • Thyroid Neoplasms
  • Urologic Neoplasms

Intervention

Biological:
Bevacizumab
Given IV
Cetuximab
Given IV
Other:
Laboratory Biomarker Analysis
Optional correlative studies
Pharmacological Study
Optional correlative studies
Drug:
Temsirolimus
Given IV
Valproic Acid
Given PO

Locations

Country Name City State
United States M D Anderson Cancer Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other The properties of the tissue microvasculature. The properties of the tissue microvasculature measured by Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) include parameters:
volume transfer coefficient, (Ktrans), fractional volume (ve), and rate constant (kep).For each of these parameters, an exploratory analysis of change from baseline will be conducted which will include mean, median, standard deviation, and 95% confidence limits.
Up to week 4 of course 1
Primary Maximum tolerated dose (MTD) of bevacizumab, defined as the dose level below the dose at which 2 of 6 patients experience drug-related dose limiting toxicity (DLT) Graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. 4 weeks
Primary MTD of temsirolimus, defined as the dose level below the dose at which 2 of 6 patients experience DLT Graded by the NCI CTCAE version 3.0. 4 weeks
Secondary Anti-tumor efficacy of each combination (objective response) Will be determined by Response Evaluation Criteria In Solid Tumors and World Health Organization criteria Up to 6 years
Secondary Levels of surrogate anti-angiogenesis markers Correlated with anti-tumor activity. Up to week 4 of course 1
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Active, not recruiting NCT02243592 - Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment
Completed NCT03445572 - Meditative Slow Breathing or Isha Kriya Meditation in Improving Cancer-Related Symptoms in Hospitalized Participants With Cancer N/A
Active, not recruiting NCT02860039 - High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant Phase 2
Completed NCT01946217 - Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials N/A
Completed NCT01635413 - Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial) N/A
Completed NCT00026169 - Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure Phase 1
Recruiting NCT04534075 - Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial Phase 3
Active, not recruiting NCT01806129 - Reproductive Health Program in Patients With Cancer N/A
Recruiting NCT03915717 - Observational Study of Outcomes After EchoMark and EchoSure-based Free Flap Monitoring
Recruiting NCT02280161 - Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer
Recruiting NCT05520281 - Short-term Psychodynamic Psychotherapy in Serious Physical Illness N/A
Terminated NCT00532064 - Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy
Completed NCT04990882 - FAPI PET/CT Prospective Interobserver Agreement
Completed NCT01896778 - Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer N/A
Recruiting NCT05770102 - DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition Phase 2/Phase 3
Recruiting NCT06090266 - A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT05886764 - Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials N/A
Completed NCT01506440 - Cognitive Assessments in Patients With Cancer Undergoing Chemotherapy
Completed NCT01432431 - Spiritual Care in Improving Quality of Life of Patients, Caregivers, and Hospital Staff N/A